APA (7th ed.) Citation

Gadgeel, S., Soria, J., Felip, E., Cobo, M., Lu, S., Syrigos, K., . . . Goss, G. (2017). 2061 - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): Analysis of tumour and serum biomarkers and long-term responders. European Journal of Cancer, 72, S185. https://doi.org/10.1016/S0959-8049(17)30671-8

Chicago Style (17th ed.) Citation

Gadgeel, S.M, et al. "2061 - Second-line Afatinib Vs Erlotinib for Patients with Squamous Cell Carcinoma (SCC) of the Lung (LUX-Lung 8 [LL8]): Analysis of Tumour and Serum Biomarkers and Long-term Responders." European Journal of Cancer 72 (2017): S185. https://doi.org/10.1016/S0959-8049(17)30671-8.

MLA (9th ed.) Citation

Gadgeel, S.M, et al. "2061 - Second-line Afatinib Vs Erlotinib for Patients with Squamous Cell Carcinoma (SCC) of the Lung (LUX-Lung 8 [LL8]): Analysis of Tumour and Serum Biomarkers and Long-term Responders." European Journal of Cancer, vol. 72, 2017, p. S185, https://doi.org/10.1016/S0959-8049(17)30671-8.